| Company/Division name | Pending Tariffs- AstraZeneca |
| Parent company | AstraZeneca |
| Type of work | Manufacturing |
| Reshoring category: | Foreign Direct Investment |
| Year reshoring announced: | 2025 |
| Year reshoring implemented or to be implemented: | 2030 |
| Domestically, the work will be done: | In-house |
| Capital investment ($): | 50,000 |
| Country(ies) from which reshored: | United Kingdom |
| State(s) reshored to: | VA |
| If relevant, work nearshored to: | - |
| Industry(ies): | Chemicals |
| Product(s) reshored | oral GLP-1 drugs |
| What domestic positive factors made reshoring more attractive? | Automation/technology |
